Article · Wikipedia archive · Last revised Jul 24, 2026

SER150

SER150 is an inhibitor of thromboxane synthase and an antagonist of the thromboxane prostanoid receptor. It was developed for diabetic nephropathy.

Last revised
Jul 24, 2026
Read time
≈ 1 min
Length
136 w
Citations
3
Source
Wikipedia ↗
SER150
Clinical data
Other namesEV 077; ICI 192605 (racemic)
Identifiers
  • (4Z)-6-[(2R,4R,5S)-2-(2-Chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC22H23ClO5
Molar mass402.87 g·mol−1
3D model (JSmol)
  • C(/C=C\CCC(O)=O)[C@H]1[C@H](O[C@H](OC1)C2=C(Cl)C=CC=C2)C3=C(O)C=CC=C3
  • InChI=1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m1/s1
  • Key:WHUIENZXNGAHQI-GKZDNZBASA-N

SER150 (formerly EV 077) is an inhibitor of thromboxane synthase and an antagonist of the thromboxane prostanoid receptor. It was developed for diabetic nephropathy.123

References

References

  1. Kim, Yoon Kook; Ning, Xinyuan; Munir, Kashif M.; Davis, Stephen N. (2 October 2022). "Emerging drugs for the treatment of diabetic nephropathy". Expert Opinion on Emerging Drugs. 27 (4): 417–430. doi:10.1080/14728214.2022.2155632. PMID 36472144.
  2. McFarlane, Samy I. (2020). Kidney Disease in Diabetes. Bentham Science Publishers. p. 101. ISBN 978-981-14-2199-0.
  3. Tan, Seng Kiong; Cooper, Mark E. (28 October 2023). "Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?". Expert Opinion on Emerging Drugs. 28 (4): 217–226. doi:10.1080/14728214.2023.2277762. PMID 37897430.